Novavax, Inc. (NVAX) vs Septerna, Inc. (SEPN)
Novavax, Inc. and Septerna, Inc. are both Biotechnology companies. Novavax, Inc. and Septerna, Inc. are of similar size ($1.8B and $1.8B). Septerna, Inc. grew revenue faster over the last twelve months: 13,520.1% against −61.6%. Septerna, Inc. has the higher net margin (−24.5% vs −59.9%) and the lower return on invested capital (−189.0% vs 0.00%). Across the 16 metrics below, Septerna, Inc. leads on 9 and Novavax, Inc. on 7.
Valuation
Profitability
| Metric | NVAX | SEPN | Biotechnology median |
|---|---|---|---|
| Gross margin | 78.60% | 100.00% | 65.16% |
| Operating margin | (56.58%) | (44.04%) | 0.00% |
| Net margin | (59.87%) | (24.51%) | 0.00% |
| Free cash flow margin | (10.20%) | 118.93% | 0.00% |
| Return on equity | 323.66% | (6.34%) | (57.72%) |
| Return on assets | (21.62%) | (4.94%) | (49.22%) |
| Return on invested capital | 0.00% | (189.01%) | 0.00% |
Growth
Health
Dividend
Size
Any metric, up to five companies and an Excel export Powerpack